IP Library Granted Patent US 7,641,897
Granted Patent B2
US 7,641,897 · App. 11/286,088 · Granted Jan 5, 2010

Feeder layer and serum independent embryonic stem cells

Assignee: The Board of Trustees of the Leland Stanford Junior University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,641,897
App. No.
11/286,088
Granted
Jan 5, 2010
Kind
B2
Abstract

Undifferentiated primordial stem cells are manipulated to permit their long term growth in defined media lacking serum and feeder layer cells by shifting the apoptotic balance of the cells, through increasing the activity of Bcl-2 family anti-apoptotic proteins or decreasing the activity of Bcl-2 family pro-apoptotic proteins. In some embodiments of the invention, the Bcl family protein is Bcl-2. The ES cells sustain the characteristics of undifferentiated, pluripotent stem cells during long-term serum- and feeder layer cell-free conditions, including the ability to be expanded in vitro, but maintain their potential to differentiate into mature cell types.

Claims (9)

1. A method of expanding mouse undifferentiated embryonic stem cells in the absence of feeder layer cells and the presence of leukemia inhibitory factor (LIF), the method comprising:

introducing into said stem cells a genetic construct encoding Bcl-2 operably linked to a promoter active in said cells; and

expanding said mouse undifferentiated embryonic stem cells in a medium free of feeder layer cells and serum, in the presence of LIF, for at least three weeks, while maintaining differentiative capacity.

2. A method of expanding human undifferentiated embryonic stem cells in the absence of feeder layer cells, the method comprising:

introducing into said stem cells a genetic construct encoding Bcl-2 operably linked to a promoter active in said cells; and

expanding said human undifferentiated embryonic stem cells in a medium free of feeder layer cells and serum, for at least three weeks, while maintaining differentiative capacity.

3. A method of expanding human or mouse undifferentiated embryonic stem cells in the absence of serum or serum-replacement, the method comprising:

introducing into said stem cells a genetic construct encoding Bcl-2 operably linked to a promoter active in said cells; and

expanding said human or mouse undifferentiated embryonic stem cells in a medium free of serum or serum replacement for at least three weeks, while maintaining differentiative capacity.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 28, 2010
From: STANFORD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024754/0297 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2006
From: WEISSMAN, IRVING L.; YAMANE, TOSHIYUKI; DYLLA, SCOTT
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 017561/0835 →
Continuity (2)
Provisional Application 6063085000 · Nov 23, 2004
Related Publication 20060172414A1 · Aug 3, 2006